A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

Trial Title: A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT ID: NCT01770418

Condition: Lung Neoplasms

Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

Conditions: Keywords:
Non Small Cell Lung Cancer
Cancer
Lung
Proton
Radiation

Study type: Interventional

Study phase: Phase 1/Phase 2

Overall status: Active, not recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Radiation
Intervention name: Radiation with Concurrent Chemotherapy
Description: RADIATION: Proton Radiotherapy Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions CONCURRENT CHEMOTHERAPY: Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days. Adjuvant chemotherapy is optional.
Arm group label: Proton Radiotherapy with Chemotherapy

Summary: The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

Detailed description: Conventional fractionated photon-based radiotherapy to 60-63 Gy at 1.8-2 Gy/fraction with concurrent chemotherapy remains the standard treatment practice in patients with stage III non-small cell lung carcinoma (NSCLC) with local control rates of approximately 50% and a median overall survival of just 18 months.Unfortunately, even the standard treatment has significant toxicity with approximately 40% of patients developing grade 3 or higher acute toxicities in the RTOG 9410 study.1 These outcomes are poor and more effective treatment regimens are needed. Higher doses of radiation have been hypothesized to improve local control in patients with stage III NSCLC. This is expected to translate into better overall survival.Given the significant improvements in outcome in patients receiving hypofractionation for stage I NSCLC, perhaps similar gains could be achieved if hypofractionated radiotherapy could be safely delivered to stage II-III NSCLC with concurrent chemotherapy. Hypofractionated radiotherapy may offer improvement in local control compared with conventional fractionation that may translate into improved overall survival. Furthermore, hypofractionation will shorten the time interval during which patients are receiving less aggressive chemotherapy. Proton therapy is a highly conformal radiotherapy technique that takes advantage of the proton's characteristic Bragg Peak, resulting in significant reductions in the exit dose of the treatment beam. Thus, proton therapy can substantially reduce the dose to critical structures even compared with IMRT. This study will investigate the safety and efficacy of delivering hypofractionated proton therapy with concurrent chemotherapy in patients with stage II-III NSCLC

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Pathologically confirmed invasive non-small cell lung cancer within 12 weeks prior to study registration. OR Pathologically confirmed invasive non-small cell lung cancer within 6 months prior to study registration if the patient received induction chemotherapy. - AJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III. - ECOG Performance status 0-1 within 8 weeks prior to study registration. - Patient must give study-specific informed consent on an IRB-approved consent prior to any research-related procedures or study treatment. - Patient must be at least 18 years old at the time of consent. - Patient must complete all required tests in section 4. - Lab results per the following within 4 weeks prior to study registration: - Absolute neutrophil count (ANC) >1,800 cells/mm3. - Platelets > = 100,000 cells/mm3. - Hemoglobin > =10 g/dl. The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable. - AST/SGOT and ALT/SGPT < 2.5 x the institutional upper limit of normal (IULN). - Post exploratory thoracotomy must be done > 3 weeks prior to study registration or patient did not have post exploratory thoracotomy. - PFT (pulmonary function test) with a FEV1 > 0.75 liters/second within 16 weeks prior to study registration. - Patients must be evaluated by a thoracic surgeon, pulmonologist or medical oncologist and deemed medically or surgically unacceptable for resection. Exclusion Criteria: - Evidence of distant metastasis (M1) involvement. - Prior radiotherapy to thoracic area. - Unintentional weight loss >10% within 4 weeks prior to study registration. - Pregnant and/or breast-feeding women, or patients (men and women) of child-producing potential not willing to use medically acceptable forms of contraception while on study treatment and for at least 12 months after study treatment. Pregnancy testing is not necessary for women who have had a hysterectomy or have not had a menstrual period for at least 24 consecutive months.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: University of Florida Proton Therapy Institute

Address:
City: Jacksonville
Zip: 32206
Country: United States

Facility:
Name: Northwestern Medicine Chicago Proton Center

Address:
City: Warrenville
Zip: 60555
Country: United States

Facility:
Name: Maryland Proton Treatment Center

Address:
City: Baltimore
Zip: 21201
Country: United States

Facility:
Name: Princeton ProCure Management LLC

Address:
City: Somerset
Zip: 08873
Country: United States

Facility:
Name: Oklahoma Proton Center

Address:
City: Oklahoma City
Zip: 73142
Country: United States

Facility:
Name: Hampton University Proton Therapy Institute

Address:
City: Hampton
Zip: 23666
Country: United States

Start date: March 2013

Lead sponsor:
Agency: Proton Collaborative Group
Agency class: Other

Source: Proton Collaborative Group

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01770418